Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064218 | 0.81 | ADORA2A (0.46) | KDM4EL3MBTL1ADORA2AALDH1A1TSHR | |
| SCHEMBL15545334 | 0.78 | GABRP (0.43) | KDM4EL3MBTL1ADORA2AALDH1A1MAPT | |
| SCHEMBL4064830 | 0.71 | NPSR1 (0.61) | KDM4EADORA2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4073525 | 0.70 | KDM4E (0.36) | KDM4EL3MBTL1ALDH1A1TSHRHPGD | |
| SCHEMBL26611978 | 0.69 | MTNR1A (0.45) | MTNR1AMTNR1B | |
| SCHEMBL8825192 | 0.69 | KDM4E (0.49) | KDM4EL3MBTL1ADORA2AALDH1A1MAPT | |
| SCHEMBL17927038 | 0.68 | CCR1 (0.45) | KDM4EL3MBTL1ADORA2AALDH1A1HPGD | |
| SCHEMBL2936661 | 0.65 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL22335921 | 0.65 | CYP4A11 (0.47) | KDM4EALDH1A1TSHRMAPTMTNR1A | |
| SCHEMBL15544893 | 0.64 | ADORA2A (0.42) | ADORA2AALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049490-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | KDM4E 2385/4885L3MBTL1 432/4885ADORA2A 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.